Virus Titrations. Infectious LCMV was quantitated by plaque assay on Vero cell monolayers. 7.5 X 10 ~ Vero cells were plated in 35-mm wells in 6-well dishes (Costar, Cambridge, MA). The plates were incubated at 37°C and used the following day for the assay when the cell monolayers were confluent. The medium was removed and the samples to be titrated were added to the cells (0.2 ml vol). After adsorption for 60 min at 37°C, the cells were overlaid with 3 ml of 0.5% Seakem agarose (FMC Corporation, Rockland, ME) in Medium 199 (Gibco Laboratories, Grand Island, NY) supplemented with 5% heat-inactivated fetal calf serum, antibiotics, and L-glutamine. The plates were incubated for 5 d at 37°C and then overlaid with 2.0 ml of 0.5% agarose in Medium 199 containing 0.01% neutral red (Gibco Laboratories). Plaques were scored the following day.
Antibody Titrations. LCMV-specific antibody was measured by a solid phase enzymelinked immunosorbent assay (ELISA) using purified virus as the antigen. LCMV Armstrong strain was grown in BHK-21 cells and purified on Renografin gradients as previously described (12) . The purified virus was diluted in phosphate-buffered saline (PBS), sonicated to disrupt clumps, and the protein concentration was determined by Lowry's method (16) using bovine serum albumin as the standard. Microtiter plates (Linbro Titertek; Flow Laboratories, McLean, VA) were coated with 200 ng/well of viral antigen in a 0.1 ml vol. After overnight incubation at room temperature, free binding sites of the polystyrene wells were blocked with 0.15 ml/well of PBS supplemented with 10% (vol/vol) heat-inactivated fetal calf serum, 0.2% (vol/vol) Tween 20, and 0.5 mM merthiolate. After 1 h or more incubation at room temperature, antigen-coated plates were used for antibody-binding assays. Viral antigen-coated plates prepared in this manner showed a high level of binding to LCMV-specific monoclonal antibodies directed against the LCMV nucleocapsid protein and the two glycoproteins, GP-1 and GP-2 (13) . Thus, this method allows us to measure antibodies directed against the three major structural proteins of LCMV. To measure LCMV-specific antibody in the serum samples, serial threefold dilutions of the samples were incubated in antigen-coated plates for 75-90 rain at room temperature. The plates were washed three times with PBS containing 0.05% (vol/vol) Tween 20, and horseradish peroxidase-labeled, affinity-purified antibodies to mouse IgG and IgM (Boehringer Mannheim Biochemicals, Indianapolis, IN) were added. After 75-90 min incubation, the plates were washed as above and 0.1 ml of the substrate solution, consisting of 3 mM hydrogen peroxide and 2.2 mM 0-phenylenediamine in 0.1 M sodium citrate buffer, pH 5.0, was added to each well. The enzyme reaction was terminated after 30 min by adding 0.1 ml of 1 N HCI into each well. Optical densities were read (OD492) with a Titertek Multiskan photometer (Eflab, Helsinki, Finland). In all experiments, plates coated with purified measles virus (Edmonston strain) (200 ng/well) were included as controls. The LCMV-specific antibody titer was determined by subtracting the binding (0D492) to measles virus-coated plates from the binding (OD492) to LCMVcoated plates. The LCMV-specific antibody titer is expressed as the reciprocal of the highest dilution showing an OD492 reading >2 standard deviations from the OD49z reading of serum samples from mock-infected mice (average of at least six control mice).
Results

LCMV-specific CTL and Antibody Responses During Acute and Persistent LCMV
Infection. Infection of adult BALB/c WEHI mice with LCMV Armstrong induced a vigorous cellular and humoral response against the virus. Table I shows the LCMV-specific CTL and antibody response of six adult mice infected with 2 x 105 PFU i.v. of LCMV Armstrong 8 d previously. All six mice bad high levels of CTL and antibody. Such acutely infected mice cleared the virus within 8-10 d postinfection (data not shown). When BALB/c WEHI mice are infected at birth with LCMV Armstrong (by any route of injection), they become carriers with life-long viremia and contain high levels of infectious LCMV in all major organs. We have checked for LCMV-specific CTL in the spleens and lymph * CTL activity in the spleen was determined by a 5~Cr release assay. Test duration was 6-8 h. Spontaneous release was <20%. All samples were assayed in triplicate and standard error was <2%. E/T, effector/target. LCMV-specific antibody in serum was determined by an EL1SA using purified virus as antigen. 8-wk-old mice injected intravenously with 0.2 ml of medium. LCMV-specific CTL and antibody were checked 7 d later. 8-wk-old mice injected intravenously with 2 x 105 PFU of LCMV Armstrong. LCMV-specific CTL and antibody were checked 7 d postinfection. I Mice injected intracerebrally with 104 PFU of LCMV Armstrong at birth (<24 h old). LCMVspecific CTL and antibody were checked when mice were 8-wk-old.
nodes of 1-3-mo-old carrier mice in many different experiments and have not detected any CTL activity. The level of killing exhibited by spleen cells from six 2-mo-old carrier mice on LCMV-infected and uninfected syngeneic targets is shown in Table I . The killing is minimal and not significantly higher than that by spleen cells from mock-infected BALB/c WEHI mice (Table I) . In contrast to the absence of detectable CTL activity, LCMV-specific antibody was present in the sera of BALB/c WEHI carrier mice. However, the amount of antibody was low and detectable in only three out of six mice (Table I) . It should be pointed out that the ELISA test we used measures free antibody and that LCMVspecific antibody present in immune complexes in carrier mice is not detected by this method.
Effect of Normal and Carrier Environment on the Generation of LCMV-specific CTL and Antibody Responses.
To further investigate the mechanism of low responsiveness of BALB/c WEHI carrier mice to LCMV, we adoptively transferred spleen cells from carriers into irradiated normal recipients (C ---* N) and spleen cells from normal adult mice into irradiated carrier recipients (N ~ C). All recipient mice were injected intravenously with LCMV Armstrong at the time of cell transfer, and LCMV-specific antibody and CTL responses were checked 8 d postinfection. As the results in Table II show, normal irradiated mice reconstituted with normal spleen cells (N --~ N) made potent LCMV-specific CTL and antibody responses. In contrast, C ~ N mice made no detectable CTL response and a low antibody response. Since the irradiated normal recipient mice provide a source of antigen-presenting cells, this result shows that the low responsiveness of carrier spleen cells to ECMV is not simply due to a defect in antigen-presenting cells. When normal spleen cells were transferred into irradiated carrier recipients (N ~ C), there was no detectable CTL activity. This was in striking contrast to the high CTL activity seen in N ~ N mice. However, N C mice made an LCMV-specific antibody response about equivalent to N N mice. These results show that the carrier environment suppressed the LCMVspecific CTL response of spleen cells from normal adult mice but had negligible effect on LCMV-specific antibody response.
Spleen cells from LCMV carrier mice do not have a generalized defect in generating antiviral CTL responses, as shown in Table III (Table II) , we next examined whether carrier spleen cells could transfer the suppression. Irradiated normal mice were reconstituted with either (a) 5 X 10 7 spleen cells from normal mice (N ~ N), (b) 5 X 10 7 spleen cells from carrier mice (C ~ N), or (c) equal mixtures (5 X 10 7 + 5 × 10 7) of spleen cells from carrier and normal mice (C + N ~ N). One group of irradiated mice was not given spleen cells (None ~ N). In some experiments, mixtures of spleen and lymph node cells (ratio, 3:1) were used to reconstitute the irradiated mice. The results of these experiments were identical to those using spleen cells alone. All irradiated recipient mice were challenged with LCMV Armstrong at the time of the cell transfer, and, 1, 3, 6, 8, 10, and 15 d later, were checked for LCMVspecific CTL, LCMV-specific antibody, and infectious LCMV in spleens (Fig. 1) . As expected, None ~ N mice did not generate any detectable immune response against LCMV and contained high levels of virus in their spleens. N --~ N mice made strong LCMV-specific CTL and antibody responses and cleared the virus infection by day 10. Their CTL and antibody responses peaked at day 8, but the CTL activity disappeared by day 15, while antibody remained at high levels. C N mice made no detectable CTL response, a minimal antibody response * Test duration was 6-8 h. Spontaneous release was <20%. All samples were assayed in triplicate and standard error was <2%. 5 X 10 7 spleen cells from 6-10-wk-old BALB/c WEHI mice were transferred intravenously into 2-4-too-old BALB/c WEHI mice irradiated (600 rad) 1 d previously. At the time of the cell transfer all recipient mice were infected intravenously with 2 x l0 p PFU of LCMV Armstrong. LCMVspecific antibody and CTL were checked 8 d postinfection. § Not tested.
1,000-fold lower than N ~ N mice), and were unable to clear the infection. C + N ~ N mice made vigorous LCMV-specific antibody responses but poor CTL responses, and contained high levels of virus in the spleen until 15 d postinfection. Since CTL activity was measured by a 51Cr-release assay, it could be argued that LCMV-infected cells in the spleens ofN + C ~ N mice acted as "cold" competitors in the cytotoxicity assay, thus exerting a pseudosuppressive effect. This was tested by mixing spleen cells from C + N ~ N mice with spleen cells from N ---* N mice * 5 x 107 spleen cells from 6-10-wk-old BALB/c WEHI mice were transferred intravenously into 2-4-too-old normal BALB/c WEHI mice irradiated (600 rad) 1 d previously. At the same time, all recipient mice were infected intravenously with 106 PFU of vaccinia virus (IHD-J strain). * Mice were sacrificed 7 d postinfection and CTL activity was checked on vaccinia virus-infected and uninfected B.10.D2 (H-2 a) targets in a 6 h n~Cr release assay. Spontaneous release was 15-30%. The data shown is percent specific killing at an effector/target ratio of 50:1.
in a 1:1 ratio during the 51Cr-release assay; however, no inhibition occurred (data not shown). Thus, the low level of killing by spleen cells from C + N ~ N mice does represent fewer CTL. Our results show that spleen cells from carrier mice actively suppress the LCMV-specific CTL response of normal adult spleen cells. The suppression is specific for the CTL response and has no effect on LCMV-specific antibody response. The kinetics and magnitude of the LCMVspecific antibody response were similar in N ~ N and C + N ~ N mice. The LCMV-specific antibody was predominantly (>80%) of the IgG class in both N --* N and C + N ~ N mice (data not shown). It should be noted that N ~ N mice that made both antibody and CTL responses against LCMV cleared virus from their spleens by day 10, whereas C + N --* N mice that made potent LCMVspecific antibody responses but poor or undetectable CTL responses contained high levels of infectious LCMV in their spleens at day 15. mice contained high levels of infectious LCMV (Table IV) . The mice were sacrificed 99 d after infection, at which time we found high levels of LCMV in the spleens, lymph nodes, thymuses, kidneys, and brains of all C ~ N and C + N ~ N mice tested (Table IV) . Thus, these C ~ N and C + N ~ N mice became long-term carriers. Most interestingly, C + N ~ N mice failed to clear the virus infection despite making a strong LCMV-specific antibody response. Taken together, these results demonstrate that the establishment of persistent LCMV infection is associated with the suppression of LCMV-specific CTL response. We next tested whether the transfer of spleen or lymph node cells containing LCMV-specific CTL would result in virus clearance and prevent establishment of the carrier state. Spleen or lymph node cells from normal adult mice infected 8 d previously with LCMV Armstrong were used as a source of LCMV-specific CTL. 5 × 107 day 8 spleen or lymph node cells were mixed with 5 x 107 carrier spleen cells and transferred intravenously into irradiated normal mice. At the time of the cell transfer all recipient mice were infected with LCMV Armstrong. Mice were sacrificed at days 3 and 7 postinfection and the virus titer in various organs and sera was determined by plaque assay on Vero cells (Table V) . As before ( Fig. 1 and Table IV), mice reconstituted with carrier spleen cells alone contained high levels of virus. In contrast, mice reconstituted with mixtures of spleen cells were sonicated, titration of the sonicated lysate revealed that 4 x 10 5 PFU of LCMV were transferred into each recipient. We have found that injection of up to 10 7 PFU of LCMV Armstrong induces a CTL response, and that the infection is cleared within 8-10 d (data not shown). This suggested that, if suppression of CTL response was due to the carried-over virus, the LCMV present in spleens of carrier mice may be a genetic variant or in a form that induces suppression. To check this possibility, LCMV was isolated from the spleens of 2-mo-old carrier mice infected at birth with LCMV Armstrong. Spleens from three carrier mice were pooled, homogenized, and titrated on Vero cell monolayers. Well-isolated plaques were picked and subjected to two additional cycles of plaque to plaque purification and then grown up in BHK-21 cells. Four such triple-cloned LCMV spleen isolates, clones 1, 3, 13, and 14, were tested for their ability to induce LCMV-specific CTL and antibody responses (Table VII) In other experiments we tested the reactivity of CTL generated during infection with LCMV clones 1, 3, and 14 on targets infected with the homologous LCMV clones and found minimal killing (<20%) in all instances (data not shown). Thus, the data in Table VII showing limited CTL activity after infection with the LCMV spleen isolates represent fewer CTL and not the lack of appropriate targets. All four LCMV spleen isolates induced good LCMV-specific antibody responses. The amount of LCMV-specific antibody made after infection with the spleen isolates was equivalent to that induced by LCMV Armstrong. Thus, infection of N ~ N mice with LCMV spleen isolates from carrier mice resulted in good antibody responses, poor CTL responses, and an inability to clear the virus. The same pattern of LCMV-specific immune responses and outcome of infection was seen in C + N N mice. These results suggest that the suppression of LCMV-specific CTL responses and the establishment of persistent infection by carrier spleen cells is due to the presence of genetic variants of LCMV in carrier mice. This was further tested by coinfecting N ~ N mice with LCMV Armstrong and LCMV clone 13, and then checking CTL and antibody responses and the presence of virus (Table VIII) . LCMV clone 13 selectively suppressed the CTL response and had no effect on the antibody response. Moreover, the CTL suppression was associated with an inability to clear the virus, and all N ~ N mice infected with LCMV clone 13 or coinfected with LCMV Armstrong and LCMV clone 13 became long-term carriers. High levels of infectious LCMV were present in the sera of these mice at 90 d after infection. Thus, the results presented in Tables  VII and VIII show that active suppression of CTL responses by carrier spleen cells and the associated persistent infection are due to genetic variants of LCMV in spleens of carrier mice.
Suppression of LCMV-specific CTL Response Is Associated with the Establishment of
Discussion
We have examined the interaction between LCMV and the host's immune system and defined conditions that lead to viral clearance or persistence. Our study establishes the following major points: the results of the present study along with the other reports clearly establish that LCMV-specific CTL play a crucial role in clearing virus during acute infection and in preventing the establishment of persistent infection.
The genetic variants of LCMV that suppress CTL responses were isolated from spleens of 2-too-old carrier mice infected at birth with triple plaque-purified LCMV Armstrong. We have found that 10 of 10 LCMV clones derived from that original wild-type LCMV Armstrong induced potent CTL responses (R. Ahmed, unpublished data). Thus, the original inoculum was homogeneous in this respect, and it is most likely that LCMV variants that suppressed CTL responses emerged during the infection in vivo. Other investigators (21, 22) have reported the presence of LCMV variants with different biological properties and plaque phenotypes in the brains and livers of carrier mice. The unique aspect of our studies is the dramatic difference we have identified in LCMVspecific CTL responses generated by LCMV variants isolated from spleens of carrier mice compared with those generated by the wild-type LCMV initially used to infect these mice. The variants suppressed CTL responses, leading to the important biological consequence of virus persistence. In striking contrast, wild-type LCMV induced a potent CTL response and the infection was rapidly cleared. Our results show that immunocompetent mice can become persistently infected when they are challenged with the appropriate LCMV variant. N ~ N mice infected with clone 13 were unable to eliminate the virus infection and became long-term carriers. Such mice have now been followed for 7'/2 mo postinfection and contain high levels of infectious virus in the serum and all major organs tested. Preliminary results indicate that adult immunocompetent BALB/c WEHI mice infected with LCMV variants make poor CTL responses and are unable to clear the virus for at least 6 wk postinfection (R. Ahmed, unpublished data). With our finding that LCMV variants can persist in adult mice, a model is now available for assessing the initiation of virus-induced autoimmune disease, the formation and deposition of immune complexes, and the imbalance of differentiated functions with altered homeostasis in adults infected with virus. These states have previously been described only with the LCMV infections initiated in utero or at birth (5, 6, 35) . Further, our data indicate that immunocompetent adults can be at risk for developing a persistent infection when exposed to the operational variant.
The ability of several viruses, especially those with RNA genomes, to undergo rapid mutation during both acute and persistent infections has been amply documented (23) (24) (25) (26) . The majority of these studies have examined the evolution of viruses in tissue culture cells, and there have been relatively few studies analyzing genetic variation in viruses during replication in their natural hosts (23, 24) . Selection of antigenic variants of visna virus during persistence in sheep, and of equine infectious anemia (EIA) virus in horses, has been described (27, 28) . However, the role of these antigenic variants of visna virus and EIA virus in persistence and pathogenesis is unclear. The generation of LCMV variants that suppress CTL responses represents an example of a biologically meaningful selection. The LCMV-specific CTL response is important not only in virus clearance, but also in the immunopathologic process causing lethal acute choriomeningitis of adult immunocompetent mice (29, 30) . Suppression of CTL responses may, therefore, benefit both the host and the virus. If so, the selection of LCMV variants that suppresses CTL responses could represent a remarkable example of virus-host evolution towards balanced pathogenicity. Other examples of similar symbiotic relationships include the persistence of reovirus in L-929 cells and myxoma virus infections in rabbits (31, 32) .
One must consider whether the markedly low level of CTL activity detectable in mice infected with the LCMV variants (or carrier spleen cells) represents dilution of CTL as a result of disseminated infection and subsequent recruitment of LCMV-specific CTL from the spleen to other infected organs (33, 34) . Although such a dilution effect cannot be completely ruled out, the following observations suggest that low CTL activity detectable after infection with the LCMV variants is due to suppression of CTL responses. (a) CTL activity is low not only in the spleen but also in the inguinal, mesenteric, and axillary lymph nodes. (b) Virus is not cleared for at least several months, suggesting that the immune response generated during the infection is inadequate (i.e., suppressed). How do the LCMV variants suppress CTL responses? One possibility is that these variants are lymphotropic and infect LCMV-specific CTL. LCMV is not an overtly cytolytic virus and it is unlikely that infection would kill the T cell. However, functional inactivation of CTL may occur due to selective inhibition of differentiated functions. Oldstone et al. (35) have shown that infection of growth hormone-producing cells by LCMV turns off the differentiated function (i.e., growth hormone production) but does not affect the vital functions (i.e., host macromolecular synthesis and replication). Conceivably, infection of LCMVspecific CTL by the LCMV variants may inhibit their differentiation into cytolytic effector cells capable of clearing the viral infection. Another possible mechanism of suppression is based upon the findings of Fink et al. (36) and Rammensee et al. (37) that CTL responses can be inhibited if antigen is inappropriately presented on T cells. Thus, infection of T cells by the LCMV variants and the subsequent expression of viral proteins on the membrane of these infected cells may deliver a negative signal and suppress the induction of the LCMV-specific CTL response. A critical difference between these two possible mechanisms of suppression is that the first requires infection of a specific population of T cells, i.e., LCMV-specific CTL, whereas the second involves infection of any T cell. A third mechanism for CTL dysfunction is the presence of LCMV, or its antigens, in high concentration in the environment of the responding CTL. Lamb et al. (38) showed that influenza virus-specific helper T cell clones can be rendered unresponsive by high concentrations of specific antigen; suppression of CTL responses after infection with large doses of LCMV has also been reported (39, 40) . Our preliminary results indicate that LCMV variants replicate to higher levels than wild-type LCMV Armstrong in spleens of infected mice (R. Ahmed, unpublished data), supporting this possibility. Our speculations on the mechanism of CTL suppression consider only the direct effects on LCMV-specific CTL. Equally possible is that suppression may follow some effect of LCMV variants on the macrophages or helper T cells-that may be required to generate LCMVspecific CTL responses. The next steps are to sort out these possible mechanisms of CTL suppression and to characterize the structural differences between the variant virus that causes CTL suppression and the wild-type virus that induces CTL activation.
Summary
We studied the mechanism of lymphocytic choriomeningitis virus (LCMV) persistence and the suppression of cytotoxic T lymphocyte (CTL) responses in BALB/c WEHI mice infected at birth with LCMV Armstrong strain. Using adoptive transfer experiments we found that spleen cells from persistently infected (carrier) mice actively suppressed the expected LCMV-specific CTL response of spleen cells from normal adult mice. The suppression was specific for the CTL response and LCMV-specific antibody responses were not affected. Associated with the specific CTL suppression was the establishment of persistent LCMV infection. The transfer of spleen or lymph node cells containing LCMVspecific CTL resulted in virus clearance and prevented establishment of the carrier state. The suppression of LCMV-specific CTL responses by carrier spleen cells is not mediated by a suppressor cell, but is due to the presence of genetic variants of LCMV in spleens of carrier mice. Such virus variants selectively suppress LCMV-specific CTL responses and cause persistent infections in immunocompetent mice. In striking contrast, wild-type LCMV Armstrong, from which these variants were generated, induces a potent CTL response in immunocompetent mice and the LCMV infection is rapidly cleared. Our results show that LCMV variants that emerge during infection in vivo play a crucial role in the suppression of virus-specific CTL responses and in the maintenance of virus persistence.
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